BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simond AM, Muller WJ. In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches. Adv Cancer Res 2020;147:189-228. [PMID: 32593401 DOI: 10.1016/bs.acr.2020.04.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Simond AM, Bui T, Zuo D, Sanguin-Gendreau V, Rao T, Phillips WA, Cardiff RD, Muller WJ. Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer. Oncogene 2022;41:3445-51. [PMID: 35538223 DOI: 10.1038/s41388-022-02323-9] [Reference Citation Analysis]
2 Ying X, Liu B, Yuan Z, Huang Y, Chen C, Jiang X, Zhang H, Qi D, Yang S, Lin S, Luo J, Ji W. METTL1-m7 G-EGFR/EFEMP1 axis promotes the bladder cancer development. Clin Transl Med 2021;11:e675. [PMID: 34936728 DOI: 10.1002/ctm2.675] [Reference Citation Analysis]
3 Li W, Hu X, Li Y, Song K. Cytotoxicity and growth-inhibiting activity of Astragalus polysaccharides against breast cancer via the regulation of EGFR and ANXA1. J Nat Med 2021;75:854-70. [PMID: 34043154 DOI: 10.1007/s11418-021-01525-x] [Reference Citation Analysis]